Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Suke Ganmao
- Development stage
- Unknown
- Lead developer
- Dalian Aosen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Suke Ganmao is an oral fixed-dose combination medication developed and manufactured by Dalian Aosen Pharmaceutical (and its subsidiary Dalian Mingsen Pharmaceutical) for the symptomatic relief of the common cold and influenza. The formulation typically consists of paracetamol (acetaminophen), amantadine hydrochloride, chlorpheniramine maleate, caffeine, and artificial bezoar. Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis, while amantadine hydrochloride provides antiviral activity against influenza A viruses. Chlorpheniramine maleate acts as an H1-antihistamine to reduce nasal congestion and sneezing, and caffeine is included to counteract the sedative effects of the antihistamine and enhance the analgesic properties of paracetamol. Artificial bezoar is a traditional component used for its antipyretic and sedative effects. It is approved in China as an over-the-counter (OTC) treatment for respiratory symptoms including fever, headache, and sore throat.
- Brand names
- Suke GanmaoSuke Ganmao capsule
- Other names
- Compound Paracetamol and Amantadine Hydrochloride Capsule速克感冒胶囊复方氨酚烷胺胶囊
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)HRH1 (Histamine H1 Receptor)CHRM2 (M2)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Suke Ganmao.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suke Ganmao.